DiNABIOS Welcomes FDA Modernization Act 3.0 Passage

DiNABIOS AG, based in Zurich and Schlieren, Switzerland, has expressed approval of the recent U.S. Senate passage of the FDA Modernization Act 3.0. The legislation is designed to modernize drug development processes by encouraging the use of advanced, human-relevant New Approach Methodologies (NAMs) for nonclinical testing.

The Act directs the U.S. FDA to create clear qualification pathways for innovative methods such as cell-based, microphysiological, and computational systems. These methodologies aim to enhance the predictability and efficiency of drug development while reducing reliance on animal testing.

DiNABIOS executives highlight that this regulatory step is crucial for the evolution of science and industry, emphasizing the company's preparedness to support pharmaceutical clients through this transition. The Act is seen as pivotal for fostering innovation and ethical responsibility in the sector.